Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Acquired by Fmr LLC

Fmr LLC lifted its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 27.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 118,265 shares of the biopharmaceutical company’s stock after purchasing an additional 25,183 shares during the quarter. Fmr LLC owned about 0.24% of Puma Biotechnology worth $302,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Frazier Life Sciences Management L.P. grew its stake in Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after buying an additional 246,264 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Puma Biotechnology by 1.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock valued at $5,715,000 after acquiring an additional 23,600 shares in the last quarter. Great Point Partners LLC boosted its position in Puma Biotechnology by 10.6% during the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 142,916 shares during the period. American Century Companies Inc. boosted its position in Puma Biotechnology by 98.5% during the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after purchasing an additional 366,653 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Puma Biotechnology by 6.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock valued at $1,975,000 after purchasing an additional 37,684 shares in the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Price Performance

Shares of PBYI stock opened at $2.75 on Friday. The firm has a fifty day simple moving average of $2.95 and a 200-day simple moving average of $3.00. The company has a market capitalization of $134.99 million, a PE ratio of 5.73 and a beta of 1.08. Puma Biotechnology, Inc. has a twelve month low of $2.22 and a twelve month high of $7.73. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The firm had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same quarter in the previous year, the business posted $0.12 EPS. Equities research analysts anticipate that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, November 20th. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.